DBV Technologies S.A.

NASDAQ:DBVT

Biotechnology

Healthcare
$9.99 -0.95%

-$0.16 today

Market cap
$238.98M
Beta
-0.22
P/E (TTM)
-8.3
EPS (TTM)
-$0.39
52W Low $8.50High $26.19

Volume 0.17M

Average 0.24M

DBVT Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

DBV Technologies S.A.NASDAQ: DBVT

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares declines year over year

Q1 FY2026 weighted avg shares of 85.66M shares fell 10.9% year over year, behind the -7.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at +3.7% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -10.9% toward the trailing-twelve-month pace of -7.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
85.66M+11.8% QoQ
Last fiscal yearDec 2025
86.4M-10.2% YoY
LTMMar 2026
88.66M-7.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.9%——
1 year-10.2%——
3-year CAGR+3.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
86.4M USD
Year-over-year change
-10.2%
4-year CAGR
+11.9%

Weighted Avg Shares vs competitors

How DBVT compares with its peers on the latest reported figures

  • DBVT's LTM Mar 2026 weighted avg shares of 88.66M shares is the 4th highest of the 11 companies compared; the peer median is 62.69M shares.
  • Its year-over-year change of -7.8% is the lowest of 10, against a peer median of +14.3%.
  • Over three fiscal years its annual growth of +3.7% compares with a peer median of +35.8%.
DBVT Competitors Peer median
Weighted Avg Shares for DBVT and competitors
Company Period LTM YoY 3-year CAGR
ANNXAnnexon, Inc.LTM Mar 2026161.69M +14.3%+41.6%
CLLSCellectis S.A.LTM Mar 2026100.38M +2.9%+30.1%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
DBVTDBV Technologies S.A.LTM Mar 202688.66M -7.8%+3.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
ENGNenGene Holdings Inc.LTM Apr 202659.85M +25.2%+47.9%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
AMRNAmarin Corporation plcLTM Mar 202620.78M +1.0%+1.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 202619.77M —+92.6%
KRROKorro Bio, Inc.LTM Mar 20269.94M +8.7%+232.8%
Peer median (excluding DBVT) 62.69M+14.3%+35.8%

Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.71M4.8M15.73M00
Cost of Revenue9.27M20.3M06.81M17.67M
Gross Profit(3.57M)(15.5M)15.73M(6.81M)(17.67M)
Gross Margin-62.5%-322.9%100.0%——
Research & Development70.34M75.5M60.22M89.9M116.68M
Selling, General & Admin23.83M17.56M31.94M23.81M28.28M
Operating Expenses93.93M101.48M92.16M113.71M147.06M
Depreciation & Amortization8.38M20.3M13.16M6.81M7.73M
EBITDA(91.16M)(76.68M)(63.27M)(110.99M)(139.32M)
EBITDA Margin-1597.0%-1597.5%-402.3%——
Operating Income(98.61M)(96.63M)(76.43M)(120.53M)(147.06M)
Operating Margin-1727.6%-2013.1%-486.0%——
Interest Income521K406.29K3.71M2.73M601.86K
Interest Expense690K427K000
Other Income / Expenses424K427K3.71M2.73M600K
Income Before Tax(98.19M)(96.2M)(72.72M)(117.8M)(146.46M)
Pre-Tax Margin-1720.2%-2004.3%-462.4%——
Income Tax Expense(381K)70K7K(4.08M)491K
Net Income(97.81M)(96.3M)(72.73M)(113.72M)(146.95M)
Net Margin-1713.5%-2006.3%-462.4%——
EPS (Basic)(1.80)(1.25)(0.75)(1.20)(1.70)
EPS (Diluted)(1.80)(1.25)(0.75)(1.20)(1.70)
Weighted Avg Shares55.1M77.38M95.12M96.17M86.4M
Weighted Avg Shares (Diluted)55.1M77.38M95.12M96.17M86.4M

DBV Technologies S.A.

NASDAQ:DBVT

Intrinsic Alpha fair value

Locked

Current Price

$9.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.